Visiopharm
Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution.
Launch date
Employees
Market cap
-
Enterprise valuation
€53—80m (Dealroom.co estimates Aug 2019.)
Company register number 26186676
Hørsholm Capital Region of Denmark (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|
| Revenues | 9.0m | 7.5m | 11.7m | 10.0m |
| % growth | - | (17 %) | 57 % | (15 %) |
| Profit | - | (1.6m) | (2.9m) | - |
| % profit margin | - | (21 %) | (25 %) | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Growth Equity VC | ||
DKK95.0m | Early VC | ||
€13.3m | Late VC | ||
£250k | Grant | ||
N/A | Late VC | ||
| Total Funding | €26.3m | ||
Recent News about Visiopharm
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Visiopharm
Edit
ACQUISITION by Visiopharm Dec 2016